Introduction
PTPL1 (also called PTPN13, FAP-1, PTP-BAS, PTP1E), which is the nonreceptor type protein tyrosine phosphatase (PTP) with the highest molecular weight, 270 kDa, contains multiple interactive domains ( ; ). Its physiological functions are poorly documented. 1 2 PTP-BL (mouse homologue of PTPL1) KO mice present abnormal regulation of signal transducer and activator of transcription signaling in T cells ( ), mice that lack the PTP-BL PTP activity show mild impairment of motor nerve repair ( ) and we recently described the role 3 4 of this phosphatase in adipocyte differentiation ( ). 5
We reported the first evidence of the negative action of PTPL1 on cancer growth through our work on the anti-growth factor effect of antiestrogens in breast cancer ( ). Other groups have confirmed that the gene presents the characteristics of a tumor 6 -9 PTPL1/PTPN13 suppressor gene ( ; ). Its expression is frequently down-regulated or silenced through promoter hypermethylation within several tumor 10 11 types ( ; ). A mutational analysis of colorectal cancers identified different somatic mutations in PTPL1 ( ). Additionally, the 12 13 14 gene is located on chromosome 4q21, a region frequently deleted in ovarian and liver cancers ( ). In agreement with PTPL1/PTPN13 15 these data, we recently showed that PTPL1 expression is an independent prognostic marker for increased overall survival in breast cancer, indicating that PTPL1 is an important regulatory element of human breast tumor aggressiveness ( ). 16 A number of potential PTPL1-interacting partners point to a role for PTPL1 in several steps of tumor progression, such as modification of cell shape and motility, and indicate its potential role in cancer metastasis. These potential partners include PIP2 ( ), 1 TAPP1/2 ( ), EphrinB1 ( ), TRIP6/ZRP1 ( ) and PARG1 ( ), all of which are involved in the maintenance of the cytoskeleton. 17 18 19 20 In this study, we demonstrate that PTPL1 plays a critical role in breast cancer progression by acting on pathways dependent on cell-matrix interactions. We also delineate the underlying molecular mechanism of this effect, which involves a decrease of Src phosphorylation and the activation of Src substrates, FAK and p130cas. Using complementary substrate trapping, co-localization, and in PTPL1 inhibits Src activation and tumor aggressiveness.
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Materials and Methods

Immunohistochemistry
The tissue array containing selected areas of paraffin-embedded sections from primary breast cancers, benign breast tissues and lymph node metastases was obtained from SuperBioChips Laboratories. It was analyzed with anti-PTPL1(AC21 from AbCam) as previously described ( ). Staining was revealed using a standard avidin-biotin enhanced immunoperoxidase technique (R.T.U. Vectastain Kit, 21
Vector Labs). PTPL1 immunostaining was cytoplasmic. TMA was scanned with a Slide Scanner (Hamamatsu NANOZOOMER), and the cytoplasmic staining was evaluated with the Definiens developer (7.0) program (MRI, Montpellier). 
Transfection and establishment of stable cell lines
Transient transfections were carried out using the jet PEI Cationic Polymer Transfection Reagent method (Qbiogene) with a ratio 1:10 of Src/PTPL1 Wt or mutant or empty pHM6 vector.
Small interfering RNA (siRNA) transfections were carried out using the Oligofectamine reagent method (Invitrogen). The two PTPL1-specific siRNAs (Si3:7313-GGAAAGAAGAGUUCGUUUA-7331 and Si4:1028-CAGAUCAGCUUUCCUGUAA-1046), the Src-specific siRNA (1403-GAAGCUGAGGCAUGAGAAG-1421) and the control non-targeting siRNA were from MWG.
For establishing clonal cell lines, MCF-7 cells were co-transfected with a 10-fold excess of pTER vector containing a short hairpin RNA (shRNA) control or shRNA-PTPL1 (Si3) over the pY3 hygromycin-resistance expression vector by the calcium phosphate-DNA precipitation technique. Colonies growing in the presence of hygromycin B (250 g/mL, Invitrogen) were subsequently picked for μ expansion in cell lines, and PTPL1 expression was quantified by immunoblot. All experiments using transfected cells were performed at passage 4 / 1 and inhibition of PTPL1 expression was controlled over this period.
+ −
Cell invasion assay
Two days after siRNA transfection, cells were detached with trypsin-EDTA, and resuspended in 4 FBS Ham s F12/DMEM. Cells and subsequent photography.
Preparation of GST fusion proteins
pGEX-4T1 Wt and DA were produced in BL21 as previously described ( ). After one wash with Substrate-Trapping Escherichia coli 8 " buffer 20 mM Tris (pH 7.5), 100 mM NaCl, 1mM EDTA, 1 Triton X-100, 10 glycerol containing 10 mM DTT, expression level and
integrity of GST fusion proteins were verified by SDS-PAGE and Coomassie blue staining (data not shown).
Substrate trapping in vitro
Substrate trapping experiments were performed on cells treated with 10 M pervanadate for 30 min ( ). Briefly, cell lysates were 
Growth assays
For Matrigel outgrowth assays, 20,000 cells were re-suspended in culture medium containing 10 FCS (0.5 mL) and added to 24-well % plates that had been precoated with Matrigel (0.2 mL, 9.6 mg/mL) (BD Biosciences). Phase contrast optical photomicrographs were taken after five days.
Alternatively, 20,000 cells were plated in triplicate in 24-well dishes that had been coated with 10 g/cm fibronectin (Becton 
Immunoprecipitation and Immunoblot analysis
Forty-eight hours after transient transfection, cells were washed twice in ice-cold PBS and lysed in lysis buffer 40 mM Tris (pH 8), 5
[ mM MgCl , 40 mM Na P 0 , 1 Triton x-100, 10 mM EDTA, 50 mM NaF, 100 M Na VO , 1/250 aprotinin, 1 mM AEBSF . Equal 
% %
Immune complexes or 100 g of total proteins were separated on 7.5 or 10 SDS/polyacrylamide gels before immunoblotting, as μ % described ( ), with the indicated antibody. 8
Immunofluorescence microscopy
Forty-eight hours after transient transfection, HEK293 cells that had been plated on coverslips were fixed with 3.7 formaldehyde in % PBS for 15 min and permeabilized with 0.5 Triton X-100 in PBS for 10 min. Immunolabeling was performed as described ( ) with 
Statistical analysis
The results of the cell proliferation, migration, adhesion and tumor growth assays were assessed with the student s test. For ' t immunohistochemistry study, the statistical significance of differences between groups was evaluated by the Mann-Whitney test or the Wilcoxon rank sum test. All statistical tests were two sided, and P values less than 0.05 were considered to be statistically significant.
Results
PTPL1 regulates breast cancer cell aggressiveness and in vitro in vivo
We have previously shown that the PTPL1 mRNA expression level is negatively correlated with breast tumor aggressiveness ( ). In 16 this study, we compared PTPL1 expression at the protein level by immunohistochemical analysis of tissue microarray that contained 5 benign breast tissues adjacent to breast cancer, 34 primary infiltrating ductal carcinomas and 10 matched pairs of primary tumors and lymph node metastases. Although the specimens were heterogeneous, PTPL1 expression in cancers was significantly lower than in benign PTPL1 inhibits Src activation and tumor aggressiveness.
Cancer Res . Author manuscript Page / 4 13 tissues ( ). Furthermore, lymph node metastases showed significantly lower levels of PTPL1 expression than paired primary Fig. 1 and A B tumors ( ). In agreement with this result, highly invasive breast cancer cell lines (MDA MB 231, MDA MB 436 and BT 459) Fig. 1 and A C expressed lower PTPL1 levels than poorly invasive breast cancer cell lines (MCF7, T47D, ZR 75.1) ( ). Fig. S1 To directly address the role of PTPL1 in tumor aggressiveness, we engineered, from the non-invasive and poorly tumorigenic MCF-7 breast cancer cells, stable clones expressing a shRNA directed against PTPL1. PTPL1 expression was inhibited by approximately 95 in % two different shRNA-PTPL1 clones ( ). We investigated the effect of PTPL1 extinction on xenograft growth in nude mouse Fig. 2A mammary fat pads. Tumor growth from the MCF-7 shRNA-PTPL1 clones was markedly higher than that of tumors from control clones ( ), suggesting that PTPL1 actively contributes to a less aggressive phenotype. Fig. 2B 
PTPL1 affects cell growth on extracellular matrix components, cell invasiveness and adhesion
To test biological parameters associated with tumor cell aggressiveness which were quantifiable in rapid assays, we chose to in vitro downregulate PTPL1 expression by siRNA to avoid clone divergence. Five days after transfection in MCF-7 cells, PTPL1-siRNAs efficiently decreased PTPL1 expression by about 80 ( ). We first studied the growth of cells as cell monolayers on plastic and no % Fig. 3A differences were observed between cells transfected with PTPL1-siRNAs and control cells (data not shown). Considering that PTPL1
extinction is effective , we tested its effect on MCF-7 cells grown under more physiological conditions. Inhibition of PTPL1 in vivo expression increased the size of the round colonies formed by MCF-7 cells seeded on Matrigel (a reconstituted basement membrane) ( Fig.   ) . Indeed, quantification of the large colonies showed comparable increases, 2.5-fold and 3-fold, by PTPL1-siRNA3 and 3B PTPL1-siRNA4, respectively ( ). Furthermore, time-course experiments on cells plated on fibronectin, a basement membrane Fig. 3C component, revealed that cells expressing PTPL1-siRNA grew exponentially with a doubling time of 28 h, which was significantly lower than that of control cells (41 h) ( ). Similar results were obtained with two other poorly tumorigenic breast cancer cell lines (  Fig. 3D  Fig. S2 ).
These growth effects require coating with extracellular matrix components, suggesting that PTPL1 could play a role in the signaling pathways initiated by cell-matrix interactions. We then analyzed cell adhesion and invasion, which are closely related to cell-matrix Src kinase is essential for PTPL1 biological activity and knockdown of PTPL1 stimulates the Src kinase pathway Next, we sought to determine the mechanism of these effects. Some experiments have suggested that PTPL1 might inactivate Src kinase activity ( ; ). Moreover, the Src kinase family plays a major role in the regulation of focal adhesion and cell growth in vitro 18 23 induced by cell-matrix interactions in normal and malignant cells ( ; ). Thus, we hypothesized that PTPL1 regulates breast cancer cells 24 25 aggressiveness through inactivation of the Src kinase pathway. To test this hypothesis, we downregulated Src expression in PTPL1-siRNA MCF-7 cells ( ) and analyzed their capacity to grow on Matrigel and fibronectin. Although the silencing of Src protein did not Fig. 5A affect cell growth, it strongly inhibited the positive effect of PTPL1 knockdown ( ), suggesting that PTPL1 expression Fig. 5 and C B inhibits Src signaling in basal conditions. We, therefore, determined whether Src expression or activity was regulated by PTPL1 silencing. Src expression and Src Y530 phosphorylation, which locks human Src in an inactive conformation, were detectable and unaffected by PTPL1 silencing in native MCF-7 cells. SrcY419 phosphorylation, which is necessary for full Src catalytic activity, was low and only detectable after important protein loading and long E.C.L. exposure. In these conditions, SrcY419 phosphorylation was increased in the presence of PTPL1 siRNA (Fig. 5D first panel), indicating that PTPL1 inhibits Src activation. Then, we used MCF-7 cells transfected with a low amount of Src expression vector ( ) for further experiments on Src phosphorylation and signaling. The effect of PTPL1 extinction on cell growth on Matrigel Fig. 5D was comparable in cells overexpressing Src and in native MCF-7 cells ( and ). Whereas SrcY530 was unaffected, SrcY419 phosphorylation was strongly increased in the presence of PTPL1 siRNA ( ), corroborating the finding that the phosphatase Fig. 5D counteracts Src-induced effects by inhibiting Src activation. We next analyzed whether PTPL1 also affected the activation of downstream Src substrates. Upon integrin stimulation, Fak is phosphorylated on tyrosine 397 (Y397), generating a high affinity binding site for Src (25 ) . Then, Src phosphorylates Fak on tyrosine residues, which are required for the full activation of Fak. Two of these residues are Y576/577. As expected, Fak-Y576/577 phosphorylation was increased when PTPL1 was silenced ( ), although no changes were Fig. 5D observed on Y397. The activated Fak/Src complex recruits proteins involved in cell adhesion, actin dynamics, proliferation and survival, such as p130cas. The proportion of p130cas co-precipitating with FAK was clearly increased in PTPL1 silenced cells ( ). Fig. 5D PTPL1 inhibits Src activation and tumor aggressiveness.
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Src is a direct target of PTPL1
Up to now, the effect of PTPL1 on Src phosphorylation has only been described ( ; ). Next, we tested whether PTPL1 in vitro 18 23 overexpression was sufficient to change Src phosphorylation . As Src kinase is mainly expressed as an inactive form in cells, we in cellulo assessed PTPL1-induced phosphorylation changes in HEK293 cells overexpressing Src (to increase the amount of Src phosphorylated at Y419). Cells were cotransfected by expression vectors coding for wt PTPL1 or PTPL1-YF/DA, a catalytically inactive mutant of PTPL1.
In the absence of PTPL1, Src was highly phosphorylated at Y419. This phosphorylation was abolished by the overexpression of wt PTPL1, whereas it was unaffected when the catalytically inactive PTPL1-YF/DA mutant was introduced in the cells ( ). This result Fig. 6A suggested that PTPL1 phosphatase activity was essential for Src hypophosphorylation.
Today, substrate trapping is currently used to identify PTP substrates ( ). The assay was, therefore, performed on overexpressing Src and wt PTPL1 or PTPL1-YF/DA. PTPL1 and PTPL1-YF/DA both localized to the plasma membrane, as described previously ( ). In cells overexpressing wt PTPL1, Src was detected in the cytoplasm and at the plasma membrane, leading to a partial 1 colocalization with wt PTPL1 ( ). In cells overexpressing PTPL1-YF/DA, Src was strongly delocalized to plasma membrane Fig. 6D protrusions and an intense colocalization with PTPL1 was observed ( , arrows). These data clearly demonstrate that PTPL1 directly Fig. 6D regulates SrcY419 phosphorylation in intact cells.
Discussion
We have recently showed that PTPL1 expression level is an independent prognostic indicator of favorable outcome for patients with breast cancer ( ). In this study, we demonstrated that PTPL1 expression is decreased in breast cancers and metastases compared with 16 benign breast tissues. Moreover, using and animal models, we evaluated the impact of PTPL1 in breast cancer cell aggressiveness in vitro and delineated the molecular mechanism responsible for this effect. We found that PTPL1 regulates the aggressiveness of a poorly tumorigenic mammary cell line because we observed that silencing of the phosphatase led to increased tumor growth in athymic mice. In line with our findings, Spanos and collaborators ( ) have recently demonstrated that PTPL1 inhibition, induced either by the presence of 27 HPV type 16 E6 or by a short hairpin RNA strategy, induces tumor growth of murine tonsil epithelial cells when it was associated with the oncogene Ras ( ). v12 27
Here, we show that PTPL1 induces phenotypic changes of breast cancer cells that are dependent on the cell-matrix interactions, suggesting an involvement of the signaling pathways initiated by these interactions such as integrin/Fak/Src kinase signaling ( ). 25
Silencing of PTPL1 expression is associated with increased cell proliferation when the cells are coated on extracellular matrix components, although the increase is not observed when cells are plated on plastic. We also show enhanced invasiveness associated with decreased cell adhesion of PTPL1 knockdown cells. PTPL1 associates with a number of actin-associated molecules ( ), and it may play a general role in 2 modulating cell invasion through the binding and/or dephosphorylation of substrates involved in cell adhesion and migration. Indeed, PTPL1 has been implicated in the regulation of cell invasion in ovarian cancer cells. In these studies, PTPL1 regulates cell motility by negatively acting on the phosphorylation of either TRIP6, after lysophosphatidic acid stimulation ( ), or HER-2 receptor in the 28 HER-2-overexpressing SKOV3 cell line ( ). On the other hand, the non-receptor tyrosine kinase Src alters the actin cytoskeleton and the 29 adhesion networks that control cell migration and also transmits signals that regulate proliferation and cell survival ( ; ). Thus, in 24 25 human cancers, elevated Src activity has been shown to increase growth rate ( ) and migratory and metastatic potential ( ), while 30 31 inhibiting cell-cell adhesion ( ). In human breast cancers, Src activity is reported to be elevated ( ). Interaction of Src with numerous 32 33 breast cancer-associated growth factors and signaling pathways, such as prolactin ( ), EGFR ( ), ERK1/2, PI3-kinase ( ) and 34 35 36 estrogen receptor ( ), supports the notion that Src activity contributes to the growth and survival of breast cancer cells. Therefore, we 37 investigated the implication of Src signaling in the PTPL1 biological effects. We demonstrated that in MCF-7 cells interruption of Src expression inhibited PTPL1 knockdown-dependent growth induction and Src activity was increased in PTPL1 knockdown cells. There are number of candidate phosphatases for Src Y530 dephosphorylation, including cytoplasmic PTP1B ( ), Shp1 ( ), Shp2 ( ) andtransmembrane enzymes PTP ( ), PTP ( ) and PTP ( ). and corroborate the hypothesis that the metastatic spread and progression of this disease can be mitigated by blocking Src activation in tamoxifen-resistant breast cancer.
In summary, by identifying Src as the PTPL1 target in signaling pathways dependent on cell-matrix interactions, we presently describe a new mechanism by which PTPL1 inhibits tumor progression that may explain the increased aggressiveness of breast tumors expressing a low level of PTPL1 ( ). This interplay between Src and PTPL1 points to the necessity for further studies on the mechanisms by Fig. S2 which the catalytic activity of this phosphatase is regulated and reinforces the interest in new therapeutic routes combining antiestrogens and Src inhibitors.
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Figure 1
Evaluation of PTPL1 expression in breast cancer specimens A microarray of tissue sections from 5 benign tissues, 24 primary cancers and 10 paired primary cancers and lymph node metastases was immunostained with an antibody against PTPL1. Representative staining of two benign tissues and two paired primary cancers and lymph A, node metastases (magnification Gx200).
Differences in the expression of PTPL1 between benign and cancer or metastasis groups were B, assessed using the Mann-Whitney test. (P 0.0004 and P 0.0013, respectively) C, Differences in the expression of PTPL1 between cancer and = = metastasis groups were assessed using the Wilcoxon signed rank test (P 0.014).
= PTPL1 inhibits Src activation and tumor aggressiveness.
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Figure 2
Implication of PTPL1 in breast cancer cells aggressiveness Expression of PTPL1 in stable cell clones was monitored by western blot using anti-PTPL1 antibodies. The loading control was obtained A, by re-probing the membrane with anti-actin. Six-week-old mice were injected with clonal cell lines in the mammary glands. 
Figure 3
Cell growth on extra-cellular matrices of siRNA-PTPL1 transfected cells Five days after siRNA transfection, MCF-7 cells were lysed and cell extracts were analyzed by immunoblotting with anti-PTPL1 and A, anti-actin antibodies.
Mock-transfected (control-siRNA) and PTPL1-siRNA (PTPL1-siRNA) cell lines were coated on Matrigel. 
Figure 5
Implication of Src kinase activity for PTPL1 biological activity Five days after siRNA transfection, MCF-7 cells were lysed, and cell extracts were analyzed by immunoblot using anti-Src, anti-PTPL1 A, and anti-actin antibodies.
One day after siRNA transfection, cells were plated on B) fibronectin and C) Matrigel. Outgrowth of B C, 
